These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 18663364)
1. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Leng X; Lin H; Ding T; Wang Y; Wu Y; Klumpp S; Sun T; Zhou Y; Monaco P; Belmont J; Aderem A; Akira S; Strong R; Arlinghaus R Oncogene; 2008 Oct; 27(47):6110-9. PubMed ID: 18663364 [TBL] [Abstract][Full Text] [Related]
2. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695 [TBL] [Abstract][Full Text] [Related]
3. Requirement of lipocalin 2 for chronic myeloid leukemia. Arlinghaus R; Leng X Leuk Lymphoma; 2008 Apr; 49(4):600-3. PubMed ID: 18398717 [TBL] [Abstract][Full Text] [Related]
4. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model. Lin F; Monaco G; Sun T; Liu J; Lin H; Stephens C; Belmont J; Arlinghaus RB Oncogene; 2001 Apr; 20(15):1873-81. PubMed ID: 11313935 [TBL] [Abstract][Full Text] [Related]
5. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]. Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985 [TBL] [Abstract][Full Text] [Related]
6. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model. Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059 [TBL] [Abstract][Full Text] [Related]
7. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway. Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326 [TBL] [Abstract][Full Text] [Related]
8. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787 [TBL] [Abstract][Full Text] [Related]
9. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572 [TBL] [Abstract][Full Text] [Related]
10. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation. Nadarajan VS; Ang CH; Bee PC Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422 [TBL] [Abstract][Full Text] [Related]
11. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442 [TBL] [Abstract][Full Text] [Related]
12. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392 [TBL] [Abstract][Full Text] [Related]
14. Establishment of a cell line with variant BCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia. Inokuchi K; Shinohara T; Futaki M; Hanawa H; Tanosaki S; Yamaguchi H; Nomura T; Dan K Genes Chromosomes Cancer; 1998 Nov; 23(3):227-38. PubMed ID: 9790503 [TBL] [Abstract][Full Text] [Related]
15. Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid leukemia in immunodeficient mice. Cai J; Wu G; Tan X; Han Y; Chen C; Li C; Wang N; Zou X; Chen X; Zhou F; He D; Zhou L; Jose PA; Zeng C PLoS One; 2014; 9(8):e105200. PubMed ID: 25133686 [TBL] [Abstract][Full Text] [Related]
16. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433 [TBL] [Abstract][Full Text] [Related]
18. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280 [TBL] [Abstract][Full Text] [Related]
19. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. Yang X; Pang J; Shen N; Yan F; Wu LC; Al-Kali A; Litzow MR; Peng Y; Lee RJ; Liu S Oncotarget; 2016 Jun; 7(24):36382-36394. PubMed ID: 27144331 [TBL] [Abstract][Full Text] [Related]
20. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression. Tan Z; Peng A; Xu J; Ouyang M BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]